Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression - Report - MDSpire
Advertisement
Efficacy and safety of stereotactic radiotherapy in patients with HER2-positive breast cancer brain metastases following intracranial oligoprogression
Clinical Report: Assessment of Stereotactic Radiotherapy's Safety and Effectiveness
Overview
This study evaluates the safety and effectiveness of salvage stereotactic radiotherapy (SRT) in HER2-positive breast cancer patients with brain metastases after TKI therapy.
Background
HER2-positive breast cancer is associated with a high risk of brain metastases, affecting a substantial proportion of patients during their illness. The management of intracranial oligoprogression in this population remains challenging, particularly after the use of tyrosine kinase inhibitors (TKIs).
Data Highlights
Outcome
Median (95% CI)
poRT-iPFS
6.4 months (6.3–8.3)
NEST
5.2 months (4.7–6.5)
OS
9.5 months (8.6–10.6)
Key Findings
The median follow-up duration was 10.7 months.
Median poRT-iPFS was 6.4 months, with significant differences between MRI-stable (7.9 months) and MRI-progressive groups (5.5 months).
Common grade ≥3 treatment-related adverse events included diarrhoea (20%), anaemia (20%), and leucopenia (18%).
Only 5% of patients developed grade 1 radiation necrosis, with no cases of interstitial pneumonia reported.
Clinical Implications
The findings suggest that SRT may be a viable treatment option for HER2-positive breast cancer patients experiencing intracranial oligoprogression after TKI therapy. Clinicians should consider MRI-stable disease as a potential indicator for initiating SRT.
Conclusion
SRT demonstrates a favorable safety profile and significant survival benefits for HER2-positive breast cancer patients with brain metastases following TKI therapy. Further studies may help refine treatment protocols in this population.
